References
- Bertram, M. Y., Lauer, J. A., De Joncheere, K., Edejer, T., Hutubessy, R., Kieny, M.-P., & Hill, S. R. (2016). Cost–effectiveness thresholds: Pros and cons. Bulletin of the World Health Organization, 94(12), 925–930.
https://doi.org/10.2471/blt.15.164418 - Carson, R. (2012). Contingent valuation: A comprehensive bibliography and history. Edward Elgar Publishing.
- Culyer, A. J. (2016). Cost-effectiveness thresholds in health care: A bookshelf guide to their meaning and use. Health Economics, Policy and Law, 11(4), 415–432.
https://doi.org/10.1017/s1744133116000049 - Desaigues, B., Ami, D., Bartczak, A., Braun-Kohlová, M., Chilton, S., Czajkowski, M., et al. (2011). Economic valuation of air pollution mortality: A 9-country contingent valuation survey of value of a life year (VOLY). Ecological Indicators, 11(3), 902–910.
https://doi.org/10.1016/j.ecolind.2010.12.006 - Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the economic evaluation of health care programmes. Oxford university press.
- Friedman, H. S. (2021). Ultimate price: The value we place on life. University of California Press.
- Gallacher, K., Morrison, D., Jani, B., Macdonald, S., May, C. R., Montori, V. M., et al. (2013). Uncovering treatment burden as a key concept for stroke care: A systematic review of qualitative research. PLoS Med, 10(6), e1001473
https://doi.org/10.1371/journal.pmed.1001473 . - Giergiczny, M. (2006). Wycena wartości statystycznego życia ludzkiego przy wykorzystaniu metody wyborów z eksperymentami. Ekonomia i Środowisko, 2, 42–56.
- Hanemann, W. M. (1984). Welfare evaluation in contingent valuation experiments with discrete responses. American Journal of Agricultural Economics, 66(3), 332–341.
https://doi.org/10.2307/1240800 - Hutubessy, R., Chisholm, D., & Edejer, T. T. T. (2003). Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Effectiveness and Resource Allocation, 1(1), 1–13.
- Jakubiak-Lasocka, J., & Jakubczyk, M. (2014). Cost-effectiveness versus cost-utility analyses: What are the motives behind using each and how do their results differ?—A Polish example. Value in Health Regional Issues, 4, 66–74.
https://doi.org/10.1016/j.vhri.2014.06.008 - Johannesson, M., & Johansson, P. O. (1996). To be, or not to be, that is the question: An empirical study of the WTP for an increased life expectancy at an advanced age. Journal of Risk and Uncertainty, 13(2), 163–174.
https://doi.org/10.1007/bf00057866 - Markiewicz, O. (2008). Analiza opłacalności programów ochrony zdrowia na podstawie wyceny statystycznego życia i wyceny dodatkowego roku przeżycia w Polsce. Praca doktorska przygotowana pod kierunkiem prof. dr hab.Tomasza Żylicza, Uniwersytet Warszawski, Wydział Nauk Ekonomicznych, Warszawa.
- McFadden, D. (1974). Conditional logit analysis of qualitative choice behavior. Frontiers in Econometrics, New York Academic Press, 105–142.
- McCabe, C., Claxton, K., & Culyer, A. J. (2008). The NICE cost-effectiveness threshold. Pharmacoeconomics, 26(9), 733–744.
- Meyerhoff, J., & Liebe, U. (2006). Protest beliefs in contingent valuation: Explaining their motivation. Ecological Economics, 57(4), 583–594.
https://doi.org/10.1016/j.ecolecon.2005.04.021 - O’Mahony, J. F., & Coughlan, D. (2016). The Irish cost-effectiveness threshold: Does it support rational rationing or might it lead to unintended harm to Ireland’s health system?. Pharmacoeconomics, 34(1), 5–11.
https://doi.org/10.1007/s40273-015-0336-1 - Orlewska, E., & Mierzejewski, P. (2000). Polskie wytyczne przeprowadzania badań farmakoekonomicznych (projekt). Farmakoekonomika, 4(supl 1), 2–11.
- Orlewska, E., & Mierzejewski, P. (2003). Project of polish guidelines for conducting pharmacoeconomic evaluations in comparison to international health economic guidelines. The European Journal of Health Economics, formerly: HEPAC, 4(4), 296–303.
https://doi.org/10.1007/s10198-003-0185-2 - Schulman, K. A. (1991). Cost Effectiveness of Low-Dose Zidovudine Therapy for Asymptomatic Patients with Human Immunodeficiency Virus (HIV) Infection. Annals of Internal Medicine, 114(9), 798–802.
https://doi.org/10.7326/0003-4819-114-9-798 - Thokala, P., Ochalek, J., Leech, A. A., & Tong, T. (2018). Cost-Effectiveness Thresholds: the Past, the Present and the Future. PharmacoEconomics, 36(5), 509–522.
https://doi.org/10.1007/s40273-017-0606-1 - Torrance, G. W., & Feeny, D. (1989). Utilities and Quality-Adjusted Life Years. International Journal of Technology Assessment in Health Care, 5(4), 559–575.
https://doi.org/10.1017/s0266462300008461 - Torrance, G. W., & Zipursky, A. (1984). Cost-Effectiveness of Antepartum Prevention of Rh Immunization. Clinics in Perinatology, 11(2), 267–281.
https://doi.org/10.1016/s0095-5108(18)30920-5 - Vallejo-Torres, L., García-Lorenzo, B., Castilla, I., Valcárcel-Nazco, C., García-Pérez, L., Linertová, R., et al. (2016). On the estimation of the cost-effectiveness threshold: Why, what, how?. Value in Health, 19(5), 558–566.
https://doi.org/10.1016/j.jval.2016.02.020 - Williams, A. (1985). Economics of coronary artery bypass grafting. British Medical Journal (Clin Res Ed), 291(6491), 326–329.
https://doi.org/10.1136/bmj.291.6491.326 291(6491), 326–329. - Woods, B., Revill, P., Sculpher, M., & Claxton, K. (2016). Country-level cost-effectiveness thresholds: Initial estimates and the need for further research. Value in Health, 19(8), 929–935.
https://doi.org/10.1016/j.jval.2016.02.017 - Żylicz, T. (2014). Cena przyrody. Wydawnictwo Ekonomia i Środowisko.